Concise Prescribing Info
Dosage/Direction for Use
Adult: PO 100 mg/day.
May be taken with or without food.
Severe hepatic and renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Concurrent use w/ other fibrates.
Special Precautions
Patient w/ hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity w/ other fibrates. Mild to moderate hepatic and renal impairment. Patient Counselling This drug may cause dizziness, somnolence, and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for renal function. Perform periodic LFT every 3 mth for the 1st yr of treatment. Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.
Adverse Reactions
Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia. Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.
Drug Interactions
Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
ATC Classification
C10AB08 - ciprofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Disclaimer: This information is independently developed by CIMS based on ciprofibrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in